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Abstract
Superagonistic CD28-specific monoclonal antibodies (CD28SA) are highly effective activators of regulatory T-cells (Treg cells)
in rats, but a first-in-man trial of the human CD28SA TGN1412 resulted in an unexpected cytokine release syndrome. Using a
novel mouse anti-mouse CD28SA, we re-investigate the relationship between Treg activation and systemic cytokine release.
Treg activation by CD28SA was highly efficient but depended on paracrine IL-2 from CD28SA-stimulated conventional T-
cells. Systemic cytokine levels were innocuous, but depletion of Treg cells prior to CD28SA stimulation led to systemic
release of proinflammatory cytokines, indicating that in rodents, Treg cells effectively suppress the inflammatory response.
Since the human volunteers of the TGN1412 study were not protected by this mechanism, we also tested whether
corticosteroid prophylaxis would be compatible with CD28SA induced Treg activation. We show that neither the expansion
nor the functional activation of Treg cells is affected by high-dose dexamethasone sufficient to control systemic cytokine
release. Our findings warn that preclinical testing of activating biologicals in rodents may miss cytokine release syndromes
due to the rapid and efficacious response of the rodent Treg compartment, and suggest that polyclonal Treg activation is
feasible in the presence of antiphlogistic corticosteroid prophylaxis.
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Introduction
‘‘Natural’’ regulatory T-cells (Treg-cells), which leave the thymus
as functional MHC class II-restricted suppressor cells, are essential
for the prevention of autoimmunity and of overshooting immune
responses to pathogens [1]. Manipulating the size and activity of the
Tregcompartmenthas,accordingly,becomeanattractivestrategyin
thecontrolofimmunopathology[2–7].TheTregrepertoireishighly
diverse and is thought to be biased towards self recognition [8],
thereby allowing the activation of protective Treg functions by self-
antigens, including tissue-specific antigens, presented at sites of
inflammation and in secondary lymphatic tissue. It is the aim of
therapeutic strategies employing polyclonal Treg cell activation to
dispatch clones from the activated Treg pool which recognize tissue
or microbial antigens in the inflamed tissues, installing specific
protection on site while allowing the remaining Treg population to
return to a resting state.
The size and activity of the Treg compartment is crucially
dependent on signals derived from the T-cell antigen receptor
(TCR, for recognition of relevant target antigens), the high affinity
IL-2R (CD25/CD122/CD132) constitutively expressed by Treg
cells (for survival, fitness, and induction of suppressive activity [9–
11]), and CD28 (required in cis for Treg generation and activation,
and in trans for the production of IL-2 by conventional CD4
T-cells [12–16]). Accordingly, IL-2 [4,5], and stimulatory CD28-
specific mAb, so-called CD28 superagonists (CD28SA) [5,6,17]
have been used in various rodent models for Treg-based
interference with a autoimmune and inflammatory model diseases.
In particular, we and others have shown that the rat CD28-specific
superagonistic mAb JJ316 is highly effective in vivo in expanding
the size and enhancing the activity of the Treg compartment [17–
19], leading to substantial therapeutic success in rat models of
autoimmunity and inflammation (reviewed in [6]).
In contrast to the benign and anti-inflammatory behaviour of
the rat-specific CD28SA JJ316, the fully humanized human-
CD28-specific superagonistic mAb TGN1412 induced a life-
threatening cytokine release syndrome during a first-in-man trial
[20], despite being well tolerated in human primates expressing
CD28 molecules which bind TGN1412 with the same affinity as
their human counterparts [21].
The TGN1412 trial not only raises questions about the
predictive value of toxicity studies conducted in rodents and even
in closely related primate species, but, more specifically, also about
the relationship between the induction of toxic cytokine release by
CD28SA on one side, and their ability to mediate the desired
effect of polyclonal Treg activation on the other.
We have recently developed a mouse anti-mouse CD28-specific
superagonistic mAb, called D665, which fully reproduces the
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nistic antibodies specific for rat and human CD28 [22]. Here, we
make use of the genetic tools provided by the mouse system to
investigate the mechanism by which CD28SA expand Treg cells in
the rodent immune system without causing systemic cytokine
release, and to ask whether pharmacological suppression of
cytokine release would interfere with CD28SA-mediated Treg
activation.
Results
CD28SA D665 expands and activates Treg cells in vivo
C57BL/6 mice were injected with increasing doses of mAb
D665, a mouse anti-mouse CD28-specific mAb of the IgG1
subclass with superagonistic properties [22]. Spleen and lymph
node cells were analyzed 3 days later by flow cytometry. As shown
in Fig. 1A, total cellularity increased in a dose-dependent fashion
up to four-fold of control values. Most of the T-cell expansion
occurred in the CD4 T-cell compartment (Fig. 1B). Intracellular
staining for Foxp3 revealed that the most dramatic increase in cell
number was observed in the Treg subset (Fig. 1C). As shown by
monitoring of CFSE-labeled CD4 T-cells (Fig. 1D), this dispro-
portionate increase of Treg cells is, at least in part, due to
enhanced proliferation of Foxp3
+ cells. A kinetic analysis (Fig. 1E)
revealed that expansion of Treg cells peaked on day 3–5 after
application of the CD28SA. Thus at the height of the response, the
CD4 T-cell compartment of CD28SA stimulated mice contained
up to 30% Treg cells, and up to tenfold more Treg cells than
found in control mice. Transfer experiments using Treg-depleted
CD4 T-cells revealed that this dramatic increase in Treg number
is the result of expansion of pre-existing Treg cells, rather than
conversion from ‘‘conventional’’ CD4 T-cells [17] (and unpub-
lished data).
We also tested the suppresive activity of the expanded
CD4
+CD25
+ cells recovered from CD28SA-stimulated mice in
vitro using purified CFSE-labeled CD4
+CD25
2 cells as responders,
and irradiated APC and anti-CD3 as a proliferative stimulus. As
shown in Fig. 2A, CD4
+CD25
+ cells from CD28SA stimulated
mice had a more than fivefold higher suppressive activity on a per
cell basis than those from control mice, adding functional
activation to numeric increase in the Treg-promoting effect of
CD28SA.
CD28SA interferes with EAE by activating Treg cells
To test for the therapeutic efficacy of CD28SA-mediated Treg
activation, experimental autoimmune encephalomyelitis (EAE), a
mouse model for multiple sclerosis, was induced by immunization
with a myelin oligodendrocyte glycoprotein (MOG) derived
peptide. Fig. 2B shows that CD28SA application ameliorated
disease development in both, a prophylactic and a therapeutic
setting. We also asked whether as hypothesized, the beneficial
effect of CD28SA therapy was Treg cell dependent by first
depleting CD25 expressing (i.e. Treg-) cells with the rat anti-mouse
CD25 specific mAb PC61. Fig. 2B shows that thorough depletion
of Treg cells (less than 1% of CD4 cells in peripheral blood, not
shown), ablated the therapeutic activity of D665. This result
strongly supports our notion that the CD28SA suppressed EAE by
transient polyclonal activation of Treg cells, in agreement with
previous work published in rat EAE [19,23].
CD28SA driven CD4 T(reg)-cell proliferation depends on
IL-2 produced by bystander cells
In antigen-driven immune responses, conventional CD4 T-cells
utilize IL-2 as an autocrine growth factor, but also provide this
cytokine to Treg cells in a paracrine fashion, thereby increasing
their number and suppressive activity [9,10,24–27]. Accordingly,
we were interested to see whether CD28SA-induced proliferation
of conventional and regulatory CD4 T-cells in vivo is a cell-
autonomous effect, or whether alternatively, it relies on signals,
e.g. IL-2, received from other activated T-cells. First, we
confirmed the requirement of the responding CD4 T-cells to be
stimulated themselves via CD28. CFSE-labeled CD4 T-cells from
wt or CD28 knockout mice (which contain about 10 and 2% Treg
cells, respectively) were transferred to CD28 wild type mice, which
were then challenged with the CD28SA and analyzed for
proliferation 3 days later. As seen in Fig. 3A, wt CD4 T-cells
(both conventional and Treg), proliferated when stimulated by
CD28SA within a wt host, whereas CD28 deficient donor cells
failed to divide. In the converse experiment, i.e. transfer of wt CD4
T-cells into CD28 deficient hosts, proliferation of both subsets was
also impaired, pointing at the importance of bystander-derived
signals.
To investigate whether IL-2 is such an essential bystander-
derived signal, wt CFSE-labeled CD4 T-cells were transferred to
wt or IL-2 deficient hosts. Indeed, CD28SA induced hardly any
proliferation of conventional or regulatory CD4 T-cells in IL-2
deficient recipients, demonstrating the requirement for paracrine
IL-2 in the CD28SA-driven expansion of both subsets (Fig. 3B).
Treg cells prevent systemic cytokine release in CD28SA
treated mice
The dependence of CD28SA-induced CD4 T-cell proliferation
on paracrine IL-2 indicated that there had to be significant IL-2
production to drive the CD28SA response. Accordingly, sera from
CD28SA-stimulated mice were analyzed for the presence of
circulating IL-2 at 2, 4 and 24 hours after injection. However, only
minute levels of IL-2 (about 25 pg/ml, as compared to 4000 in the
TGN1412 trial [20]), were observed in the circulation of
CD28SA-treated mice (Table 1). We also investigated the levels
of other circulating cytokines (ILs 4, 5, 6, 10, 12; IFNc and TNF)
which had contributed to the syndrome observed in the human
volunteers of the TGN1412 study [20]. The highest systemic level
observed was for IL-6 at 2 hrs (168 pg/ml; compared to 3500 in
the TGN1412 study). In further experiments, samples were
collected as early as 20 min. and up to three days after application
of CD28SA, without any evidence for pathophysiologically
revelant levels of circulating cytokines (data not shown).
One plausible explanation [6] for the absence of systemic
cytokine release in CD28SA treated mice could be instantaneous
consumption of IL-2 by Treg cells, which would contribute to their
CD28SA-driven activation and result in the suppression of further
cytokine production by the conventional CD4 T-cells. We tested
this hypothesis by depletion of Treg cells from ‘‘DEREG’’ mice,
which express the human diphteria toxin (DT) receptor as well as
GFP under the control of the Foxp3 promoter, using DT [28]. We
preferred this approach over CD25-directed mAb depletion
because residual mAb would have influenced the amount of free
IL-2 due to its blockade of IL-2R. As compared to the PBS treated
control group where Treg cells comprised 12.760.92 percent of
CD4 T-cells, DT-treated DEREG mice retained only 0.6360.19
percent. As seen in Figure 4, serum samples obtained from these
Treg depleted, CD28SA treated mice after 2 and 4 hours revealed
significant levels of circulating IL-2 (200 pg/ml), IL-6 (2300 pg/
ml) and TNF (500 pg/ml), which had disappeared by 24 hours.
Of note, IFNc and ILs 4, 10 and 12 remained low, while moderate
amounts of IL-5 were detected (not shown). In contrast, no
cytokine release was induced in PBS treated DEREG mice (Fig. 4)
and in WT mice treated with DT or PBS (not shown). In
Treg Control of Cytokine Storm
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trigger the release of pro-inflammatory cytokines also in mice, with
the exception of IFNc and IL-12.
Treg activation is resistant to corticosteroid treatment
The very low levels of circulating cytokines, including IL-2, in
CD28SA stimulated mice indicate that a ‘‘cytokine storm’’ is not a
prerequisite for CD28SA-driven Treg activation. Since in humans,
however, application of the superagonist TGN1412 resulted in a
rapid toxic cytokine release, we asked whether its pharmacological
prevention would also interfere with the intended response, i.e.
transient Treg expansion and activation. To test this in the mouse
system, we induced systemic cytokine release with the bacterial
superantigen SEB [29], in the presence or absence of 5 mg/kg/
day of the corticosteroid dexamethasone (Dex), and studied the
effects on concommitant stimulation with the CD28SA. To
accommodate the rapid kinetics of TNF release in this system
[29], measurements were taken at 1 and 4 hours. As shown in
Figure 5A, high levels of IL-2, IL-6, IFNc and TNF were observed
in SEB-treated mice irrespective of simultaneous application of the
CD28SA. No significant changes were detected for ILs 4, 5, and
12 (not shown). Pretreatment with Dex three hours before SEB
injection reduced the IL-2 response by 3–5 fold, the IL-6 response
by 10 fold, the IFNc response 40 fold, and the TNF response by 5–
10 fold, indicating successful suppression of cytokine release by
corticosteroid prophylaxis.
Next, we asked whether CD28SA-driven Treg expansion and
functional activation were also impaired by Dex treatment. In
keeping with the well-established effects of corticosteroids on the
peripheral immune system, we observed a clear reduction in total
cellularity of spleen and lymph nodes (not shown). When analyzed
on day 3 after stimulation, the frequency of nTreg cells among
CD4 T-cells was enhanced, however, rather than reduced, by
coadministration of Dex to CD28SA-treated mice (Fig. 5B). This
effect was not observed in mice receiving Dex only, but was
preserved in mice receiving SEB in addition to CD28SA and Dex.
We then titrated purified Treg cells from stimulated and naı ¨ve
mice into a standard suppression assay employing conventional
CD4 responder cells, irradiated APC and anti-CD3 as a T-cell
mitogen (Fig. 5C). In all cases where the CD28SA had been
applied in vivo, and irrespective of additional in vivo treatment with
SEB or anti-phlogistic therapy with Dex, the Treg cells recovered
were five to ten-fold superior in suppressive activity as compared
to Treg cells from naı ¨ve mice. Thus, prophylactic treatment of
mice with corticosteroids at doses which efficiently control a
potential ‘‘cytokine storm’’ does not impair the Treg-promoting
activity of CD28SA.
Discussion
Our present results using a mouse-anti mouse CD28SA confirm
the preferential expansion and activation of Treg over conven-
tional CD4 T-cells initially reported in rats [17,19], and suggest a
mechanism for this effect: CD28SA-triggered activation of
conventional CD4 T-cells provides a source of IL-2, which
synergizes with the effect of CD28SA on the Treg cells themselves,
thereby supporting their expansion and functional activation. This
model [6] transfers the established IL-2 dependent regulatory
circuit described for antigen-driven T-cell responses [9,10,24–27]
to the polyclonal stimulus provided by CD28SA, with the major
modification of a more rapid onset of counter-regulation which
dampens the conventional CD4 T-cell response before it reaches
the effector phase. Most likely, one of the decisive mechanisms in
this regulatory circuit is the consumption of IL-2 by the CD28SA
activated Treg cells [30,31], leading to growth-factor withdrawal
and apoptosis [32] of the effector cells, and to further functional
activation of the Treg cells. Indeed, we found a dramatic
upregulation of Treg effector function in CD28-stimulated mice
which, together with their numeric expansion, well explains their
anti-inflammatory effects (Fig. 2A). In agreement with previous
studies performed in rats [19,23], this hyperactivation of the
regulatory T-cell compartment translates into protection from and
interference with EAE (Fig. 2B). Of note, amelioration of
inflammatory liver disease in a mouse model of African
trypanosomiasis [33] has recently added another example to the
list of rodent immunopathologies that are effectively treated by
CD28SA-mediated Treg activation.
A key finding of the present study is the rapid release of
substantial amounts of TNF, IL-6 and IL-2 into the circulation of
CD28SA-treated mice which had previously been depleted of
Treg cells, whereas no significant cytokine release is observed in
CD28SA-stimulated control animals (Fig. 4, Table 1). This
indicates that in Treg-sufficient rodents, Treg cells quickly get
the upper hand and prevent a ‘‘cytokine storm’’. In keeping with
these results and our previously published model [6], a transient
induction of cytokine mRNA, but no systemic cytokine release,
was recently reported for CD28SA treated rats [34].
In the human volunteers of the TGN1412 study, the need for
intensive medical intervention which, inter alia, included IL-2Ra-
specific mAb, precluded further analysis of CD28SA effects on
Treg cells. It is obvious from the unfortunate outcome of the trial,
however, that in contrast to rodent models, Treg cells did not
rapidly dominate the response of effector T-cells. The reasons for
this difference in overall reactivity of the human and rodent
immune systems remain elusive in spite of a number of suggestions
(reviewed in [35]). This holds equally true for the difference in
reactivity between the cynomologus monkeys used in preclinical
testing of TGN1412 itself, which had well tolerated the antibody
[36], and the human volunteers.
While it is conceivable that more than one mechanism is
involved in the marked species differences of the response to
CD28SA, the question is worth asking whether pharmacologic
suppression of systemic cytokine release is compatible with the
desired effect of the mAb, i.e. transient polyclonal Treg activation.
There is ample experience with this type of intervention [37] in
mAb therapy because cytokine release syndromes such as observed
with TGN1412 are not unique to this type of mAb but rather have
been observed with other agonistic mAb such as anti-CD3 [38,39],
but also with blocking or depleting mAb to cell surface receptors
not thought to mediate activating signals [40]. Therefore,
prophylactic and interventional protocols have been developed
to contain such ‘‘cytokine storms’’ which employ corticosteroids as
Figure 1. T-cell responses to mouse CD28SA D665 in vivo. (A) Cell numbers in pooled lymph nodes and spleen, d3. (B) T-cell subsets in lymph
nodes. (C) Frequency (%) of CD25+Foxp3+ Treg cells among CD4 lymph node T-cells (left) and their absolute numbers in pooled lymph nodes (right).
(D) Cell division of conventional and regulatory CD4 T-cells, d3 after stimulation with 100 mg CD28SA. 10
7 purified CFSE-labeled CD4 T-cells were
transferred i.v. on day 21. Average numbers of cell divisions for Foxp3-positive and –negative subsets (histogram inserts), and percentages of
recovered subsets (dot plot inserts) are indicated. (E) Kinetics of absolute Treg cell numbers in lymph nodes (left), and of percentage among CD4 cells
(right). *** indicates p,0.0001 as compared to untreated mice (d0).
doi:10.1371/journal.pone.0004643.g001
Treg Control of Cytokine Storm
PLoS ONE | www.plosone.org 4 February 2009 | Volume 4 | Issue 2 | e4643Figure 2. Suppressive activity of CD28SA stimulated Treg cells. (A) In vivo stimulation with CD28SA increases potency of Treg cells in vitro.
CFSE-stimulated indicator CD4 T-cells were cocultured with purified Treg cells from naı ¨ve or d -3 CD28SA stimulated mice at the ratios indicated, and
stimulated as given in Methods. Cell division was measured on d3, and average numbers of divisions are given as inserts. (B) CD28SA stimulation
suppresses EAE by activating the Treg compartment. Left: prophylactic, middle: therapeutic treatment. Right: Treg depletion abolishes therapeutic
effect. 50 mg of CD28SA were applied and EAE was read as given in Methods.
doi:10.1371/journal.pone.0004643.g002
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cytokines with toxic systemic activity such as TNF, IFNc, IL-6
and IL-2, all of which very rapidly reached dramatic levels in the
TGN1412 volunteers [20].
Since mice do not respond to CD28SA with significant systemic
cytokine release (Table 1) as a result of rapid Treg activation, we
tested the effects of corticosteroids in mice additionally stimulated
with a bacterial superantigen [29]. Our results (Fig. 5) show that
superantigen-mediated activation of effector-cells with the poten-
tial to release systemic pro-inflammatory cytokines, and the
simultaneous suppression of this cytokine release by corticosteroid
prophylaxis do not interfere with CD28SA-mediated Treg
activation. Interestingly, while the circulating levels of IFNc,
TNF and IL-6 as crucial mediators of immunopathogenesis were
almost completely suppressed by Dex, that of IL-2 was only 3–5
fold reduced suggesting that the effects of corticosteroids on IL-2
production stimulated by CD28 would have left sufficient ‘‘fuel’’
for the activation of Treg cells. On the side of the Treg cells
themselves, it has indeed been shown in mice that their activation
by systemic infusion of IL-2 is resistant to corticosteroid therapy
[5].
In summary, our findings indicate that the cytokine storm
observed in the TGN1412 trial was not detected in preclinal
rodent models due to the rapid control of CD28SA-induced
cytokine release by Treg cells. This Treg cell response is itself
triggered by CD28SA, in keeping with the important role of CD28
signalling in Treg homeostasis and activation, but also depends on
CD28SA stimulation of conventional T-cells, which provide
Figure 3. CD28SA mediated CD4 T-cell activation requires CD28 signals in cis and trans. 10
7 CFSE-labeled purified CD4 T-cells were
transferred on day 21 i.v. into wild type or knockout mice as indicated, and analyzed 3 d after CD28SA application. (A) Requirement for CD28 on both
donor and host cells for proliferation of transferred cells. (B) Host-derived IL-2 is required for proliferation of donor cells.
doi:10.1371/journal.pone.0004643.g003
Table 1. Circulating cytokine levels after CD28SA injection.
Cytokines Control level Days after CD28SA injection
2h 4h 2 4h
IL-2 ND 26.4368.50 12.8465.17 ND
IL-4 0.4960.44 1.9660.90 1.8760.95 1.5961.50
IL-5 0.1160.18 1.1160.20 4.9161.68 25.9763.67
IL-6 1.7161.62 168.16654.67 125.09672.06 7.2163.61
IL-10 0.2160.16 9.8663.48 78.15654.44 6.94610.01
IL-12p70 0.1360.23 ND 0.8861.53 15.21618.13
IFNc 0.4260.37 3.6663.41 1.0860.12 2.2860.32
TNF ND 27.97624.73 56.07671.20 ND
Groups of three mice received a single injection of 100 mg mAb D665. Mice
were sacrificed at times indicated, and cytokines in sera were measured by
cytokine bead array analysis. Values are given as pg/ml. ND=not detectable.
doi:10.1371/journal.pone.0004643.t001
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cytokine delivery does, however, not preclude the use of
corticosteroids to suppress of pro-inflammatory cytokine release,
which provides an important safety shield in mAb therapies.
On a more general note, the marked ability of Treg cells to
prevent systemic cytokine release in mice should be taken into
account in current and future preclinical rodent studies of
immunomodulatory biopharmaceuticals. In practice, toxicity
testing in Treg depleted mice may be helpful in predicting such
a possible inflammatory response.
Materials and Methods
Ethics statement
All animal experimentation was performed under permit by the
Government of Lower Franconia in accordance with the state
regulations guidelines for animal welfare.
Mice
C57BL/6 and BALB/c mice purchased from Harlan Winkel-
mann (Borchen, Germany). Congenic Thy1.1 mice and CD28
2/2
mice were from Jackson Laboratories. IL-2-deficient mice [41] on
a C57BL/6 background were derived at the Institute, and
DEREG mice [28] were generously provided by Tim Sparwasser.
Mice between 6–10 weeks of age were used and maintained in the
institute’s barrier-facility.
MAb treatment
MAb D665 [22] was bioreactor-produced by Exbio, Praha,
Tchec Republic, Invivo Biotech, Henningsdorf, Germany, or
Serotec, Oxford, UK. PV-1 was used as negative control. All
preparations were in a low-endotoxin format and injected i.p.
Indistinguishable results were obtained with i.v. injection. Unless
stated, 100 mg/mouse were used.
EAE induction and treatment with CD28SA in vivo
Active EAE was induced in C57BL/6 mice by immunization
with 50 mg MOG35–55 (Institute of Medical Immunology, Charite ´,
Berlin, Germany) in PBS emulsified in an equal volume of CFA
containing Mycobacterium tuberculosis H37RA (Difco, Detroit
MI, USA) at a final concentration of 1 mg/ml. 200 ng pertussis
toxin (List Biochemicals, Campbell, CA, USA) were given i.p. on
day 0 and 2. Mice were scored daily according to a 10 point
scale[42]. CD28SA was given as a single i.p. injection of 50 mgo n
the day of immunization (preventive setting) or on day 9
(therapeutic setting). In some experiments, Treg were depleted
by 6 i.p. injections of 100 mg anti-CD25 (clone PC61) every third
day followed by EAE immunization using 25 mg MOG35–55.
Induction of systemic cytokine release and corticosteroid
treatment
BALB/c mice received a single intravenous injection of 50 mgo f
bacterial superantigen - SEB (Staphylococcal Enterotoxin B).
Additionally they were stimulated with 200 mg of CD28SA. This
was performed in the presence or absence of 5 mg/kg dexameth-
asone (Dex) pre-treatment (3 hours before SEB/CD28SA), with
subsequent daily injections of Dex.
Antibodies used for flow cytometric analyses and for
purification of T-cells
CD4 (RM4-5), CD25 (PC61 or 7D4), CD8 (53–6.7), CD3
(17A2), B220 (RA3-6B2), Thy1.1 (OX-7). CD11b (M1/70),
CD49b (Dx5), B220 (RA3-6B2), TER-119 (TER-119): BD
Pharmingen, Foxp3-(FJK-16s): eBioscience.
Cytokine detection
For detection of serum cytokines ELISA sets (OptEIA
TM,B D
Pharmingen) and Cytometric Bead Array (CBA, BD Pharmingen)
were used according to the manufacturer’s instructions.
Flow cytometry
Single cell suspensions were incubated with anti-CD16/CD32
mAb (2.4G2; Fc block, BD Pharmingen) followed by staining of
extracellular markers. Foxp3 analysis was performed according to
the manufacturer’s instructions (eBioscience). Acquisition per-
formed on a FACSCalibur
TM and data were analyzed using
FlowJo software (Beckton Dickinson).
Purification of T-cells
Single-cell suspensions were stained with a cocktail of biotin-
labeled antibodies, followed by incubation with Streptavidin
MicroBeads. CD4
+ T-cells were prepared by negative selection
using the MACS separation system (Miltenyi Biotech). CD25
+ and
Figure 4. Treg depletion results in systemic cytokine release
after CD28SA stimulation. Mice were pretreated with DT to remove
Treg cells from DEREG mice as given in Methods, and stimulated with
CD28SA for the times indicated. Cytokine levels in peripheral blood are
shown.
doi:10.1371/journal.pone.0004643.g004
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2 CD4 T-cells were separated using PE labeled anti-CD25
mAb and anti-PE- MicroBeads. Purity of cells was 90–95%.
CFSE-labeling and Cell Transfer
Purified CD4 T-cells were labeled with 10 mM CFSE at RT for
5 min. 10
7 cells in PBS were transferred i.v. one day before
CD28SA stimulation.
Treg cell depletion
DEREG mice were treated daily with intraperitoneal injection
of diphteria toxin (DT; 1 mg) for five days before administration of
CD28SA. Control groups received PBS instead of DT or
CD28SA. Efficiency of depletion was monitored by flow
cytometric analysis of GFP positive cells.
Suppression Assay
Isolated CD4
+CD25
2 responder T-cells (5610
4) were CFSE
labeled and cultured for 3 days in U-bottomed 96-well plates with
a various dilutions of purified CD4
+CD25
+ Treg cells in the
presence of soluble anti-CD3 (1 mg/ml) and irradiated splenic
APC (20Gy; 2610
5). Proliferation was assayed by CFSE dilution.
Statistical analysis
Statistical significance for normal distributed samples was
analyzed by unpaired t-test. Data with unequal variances were
tested with Mann-Whitney rank sum test using GraphPad Prism
Software. Values of p,0.05 were considered significantly
significant.
Figure 5. CD28SA mediated Treg activation is compatible with anti-phlogistic corticosteroid therapy. (A) Dexamethasone (Dex)
effectively suppresses cytokine release induced by the superantigen SEB in the presence or absence of CD28SA stimulation. Sera of mice treated as
indicated (see also Methods) were analyzed 1 hr (closed bars) or 4 hrs (stripped bars) after stimulation with SEB and/or CD28SA. (B) Increase in Treg
cells is unaffected by Dex treatment. Analysis on day 3 after single stimulation with SEB and/or CD28SA, and daily treatment with 5 mg/kg Dex. (C)
CD28SA-induced enhancement of Treg activity is resistant to Dex treatment. Treg cells isolated from groups shown in (B) were cocultered with CFSE-
labeled indicator cells as described in Methods. Cell division was measured on d3, and average numbers are given as inserts.
doi:10.1371/journal.pone.0004643.g005
Treg Control of Cytokine Storm
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